

New generation of antibiotics for Gram–negative bacteria

Boulos & Cooper Pharmaceuticals have discovered a second generation of antibiotics which show broad spectrum activity, including activity against pandrug-resistant Gram-negative bacteria. This builds on the company's first generation of antibiotics which belong to a new class of styrylbenzene antibiotics with a novel mechanism of action.

Chief Executive Officer, Dr Ramiz Boulos said “We are very excited about this new discovery; it proves the versatility of our technology and shows that we are able to deliver multi-generational antibiotics belonging to this new class.”

Boulos & Cooper Pharmaceuticals are now expanding their drug development pipeline and adding new programs to address other infectious diseases caused by bacteria.

For further information and photographs, please contact:

Dr Ramiz Boulos
Chief Executive Officer
email: ceo@bouloscooper.com
telephone: +61 431 150 538